Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
4.745
+0.025 (0.53%)
May 14, 2026, 11:45 AM EDT - Market open
Verastem Revenue
Verastem had revenue of $18.67M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $49.59M, up 395.85% year-over-year. In the year 2025, Verastem had annual revenue of $30.91M with 209.14% growth.
Revenue (ttm)
$49.59M
Revenue Growth
+395.85%
P/S Ratio
8.36
Revenue / Employee
$486,127
Employees
102
Market Cap
416.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.91M | 20.91M | 209.14% |
| Dec 31, 2024 | 10.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
| Dec 31, 2018 | 26.72M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Enanta Pharmaceuticals | 69.21M |
| Invivyd | 53.43M |
| C4 Therapeutics | 34.86M |
| X4 Pharmaceuticals | 9.01M |
| PureTech Health | 4.66M |
VSTM News
- 3 hours ago - Verastem price target lowered to $14 from $16 at Mizuho - TheFly
- 2 days ago - Verastem Oncology to Present at Upcoming Investor Conferences - Business Wire
- 6 days ago - Verastem price target lowered to $18 from $19 at BTIG - TheFly
- 6 days ago - On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer - Business Wire
- 6 days ago - Verastem price target raised to $18 from $16 at Alliance Global - TheFly
- 6 days ago - Verastem reports Q1 adjusted EPS (43c), consensus (47c) - TheFly
- 6 days ago - Verastem Earnings Call Transcript: Q1 2026 - Transcripts
- 6 days ago - Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates - Business Wire